| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | 42.86% | Ascendiant Capital | → $2.5 | Initiates Coverage On | → Buy |
| 08/13/2021 | 471.43% | Roth Capital | $11 → $10 | Maintains | Buy |
| 05/18/2021 | 528.57% | Roth Capital | $12 → $11 | Maintains | Buy |
| 01/11/2021 | 585.71% | Craig-Hallum | → $12 | Initiates Coverage On | → Buy |
| 01/05/2021 | 585.71% | Roth Capital | → $12 | Initiates Coverage On | → Buy |
What is the target price for Vivos Therapeutics (VVOS)?
The latest price target for Vivos Therapeutics (NASDAQ: VVOS) was reported by Ascendiant Capital on January 17, 2023. The analyst firm set a price target for $2.50 expecting VVOS to rise to within 12 months (a possible 42.86% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vivos Therapeutics (VVOS)?
The latest analyst rating for Vivos Therapeutics (NASDAQ: VVOS) was provided by Ascendiant Capital, and Vivos Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for Vivos Therapeutics (VVOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vivos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vivos Therapeutics was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
Is the Analyst Rating Vivos Therapeutics (VVOS) correct?
While ratings are subjective and will change, the latest Vivos Therapeutics (VVOS) rating was a initiated with a price target of $0.00 to $2.50. The current price Vivos Therapeutics (VVOS) is trading at is $1.75, which is within the analyst's predicted range.